StockNews.AISignal intelligence
Company intelligence

GRAL

GRAIL, Inc. · NASDAQ · Healthcare

Price$115.89-4.50% · −$5.46
Market cap5.21BEquity value
P / E-11.9Trailing ratio
Volume361.13KLatest session
Market data

GRAL price chart

TradingView
Related signals
1 min delayed

Browse public GRAL signals with their source context and measured market impact. Open any signal for its permanent analysis page.

GRALSep 24, 2026+6.45% since signal

GRAIL's Galleri Advances in Safety Review as FDA Decision Looms

GRAIL's Galleri test won a favorable safety vote from an FDA advisory panel, but experts remain divided on effectiveness, and a prior study raised detection concerns for later cancers. The FDA decision remains pending, with potential to unlock a sizable commercial opportunity if approved, while efficacy questions could temper upside and adoption.

View signal analysis
GRALSep 21, 2026+1.20% since signal

FDA Staff Finds No Major Issues for Grail's Cancer Test; Shares Surge

FDA staff reviewers did not raise major concerns about Grail's blood test for more than 50 cancers, signaling a favorable regulatory disposition. The positive tone spurred a 35% intraday jump, underscoring investor anticipation of a cleared or expanded-use path. If momentum persists, GRAL could see renewed attention on its pipeline and longer-term growth prospects.

View signal analysis
GRALAug 10, 2026+2.34% since signal

GRAIL faces pivotal FDA panel review for Galleri cancer test

GRAIL is preparing for a pivotal FDA panel review of its Galleri cancer diagnostic tool, a potential catalyst for commercialization and valuation. The panel assessment could determine the tool's regulatory fate, influencing reimbursement discussions and investor sentiment. Until a decision, GRAL shares may remain volatile as guidance and expectations evolve.

View signal analysis
GRALAug 7, 2026+12.57% since signal

Grail's Galleri FDA Advisory Meeting in September Could Buckle Near-Term Upside

Grail disclosed that the FDA plans to convene outside experts to review Galleri in September, a regulatory milestone that sparked about a 4% pre-market gain. The advisory meeting could act as a near-term catalyst for Galleri's path to broader acceptance, though no decision date was provided. Investors should watch committee feedback and any signaling on trials or labeling that could influence adoption and reimbursement.

View signal analysis
Research

Company intelligence